XSTO
ACARIX
Market cap24mUSD
Oct 07, Last price
0.22SEK
1D
-0.92%
1Q
-16.34%
Jan 2017
-98.62%
IPO
-98.03%
Name
Acarix AB
Chart & performance
P/E
—
P/S
32.81
EPS
—
Div yield, %
—
Shrs. gr., 5y
60.28%
Rev. gr., 5y
27.67%
Revenues
7m
+18.69%
Net income
-48m
L-27.34%
CFO
-48m
L-23.60%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Acarix AB (publ) is a medical technology company that develops and introduces diagnostic solutions for cardiovascular conditions to markets including Germany, Sweden, the Middle East, Switzerland, Austria, and globally. Their key product is the CADScor System, an exceptionally sensitive, non-invasive analytical device designed for the detection of coronary artery disease. Founded in 2009, Acarix AB (publ) maintains its headquarters in Malmö, Sweden.
Key people
Werner Braun
Chairman of the Board · since 2016
Christian Lindholm
Chief Financial Officer · since 2016
Claus Bo Voge Christensen
Chief Operating Officer · since 2009
Anja Schaefer
Chief Marketing Officer · since 2016
Yun Fei Hong
Director · since 2016
Headquarters & legal address
HYLLIE BOULEVARD 34 5 TR
MALMÖ, M 215 32
SE
MALMÖ, M 215 32
SE
Previous name
Acarix AB (publ)
Previous name
Goldcup 10596 AB
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||